Local pharmaceutical groups in Jakarta have decried a draft law aimed at a drug patents crackdown by the government. The roaring medicine business in the city is attributed to several copies of same drugs being sold. And there is nothing to stop any of Indonesia's 240 drug companies from launching copies in the market.
The current draft law is designed to bring Indonesia's trade-related intellectual property rights (trips) laws in line with requirements stipulated under the World Trade Organization (wto). Now, the issue has become a bone of contention between a government keen to please the wto and local firms afraid of incurring losses in a sector that generates us $650 million per year.
The firms denounce a trips requirement that renders imports of patented raw materials illegal, unless obtained from the product's originator. They want the government to decree that raw materials for some of the products -- belonging to the us-based Pfizer, Belgium's ucb and Sweden's Astra, for instance -- be exempted.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.